A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Trial Profile

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Ivosidenib (Primary)
  • Indications Cholangiocarcinoma; Chondrosarcoma; Glioma
  • Focus Adverse reactions
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 17 Nov 2017 Data (n=35) presented in an Agios Pharmaceuticals Media Release.
    • 17 Nov 2017 According to an Agios Pharmaceuticals media release, updated data from glioma expansion cohort were presented at the Society for NeuroOncology Annual Meeting.
    • 30 Oct 2017 Results of a gene expression analysis presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top